Upstream Bio Inc.
Industry: Health Care – Biotechnology: Pharmaceutical Preparations
Stock Symbol: UPB – NASDAQ
Animal Usage: Animal Testing
Our Opinion
In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation.
https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-announces-first-patient-dosed-phase-2-clinical